Cannabis compound tested as boost for Toughest-to-Treat psychosis

NCT ID NCT07326124

Summary

This study is testing whether adding a purified cannabis compound called cannabidiol (CBD) can improve the effects of the antipsychotic drug clozapine for people with severe, treatment-resistant psychosis. About 250 participants who haven't responded well to clozapine alone will take either CBD or a placebo pill for 12 weeks, in addition to their regular clozapine treatment. Researchers will measure changes in symptoms, thinking, and quality of life to see if CBD helps.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Cambridgeshire and Peterborough NHS Foundation Trust

    Cambridge, United Kingdom

  • Charité Universitätsmedizin

    Berlin, Germany

  • Geha Mental Health Center

    Petah Tikva, Israel

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Ludwig-Maximilian-University Munich

    Munich, Germany

  • National and Kapodistrian University of Athens

    Athens, Greece

  • Oxford Health NHS Foundation Trust

    Oxford, United Kingdom

  • Psychiatric University Hospital (PUK), Zurich

    Zurich, Switzerland

  • Shalvata Mental Health Center

    Hod HaSharon, Israel

  • Sheba Medical Centre

    Ramat Gan, Israel

  • Stichting Amsterdam UMC

    Amsterdam, Netherlands

  • University Hospital Cologne

    Cologne, Germany

  • University of Campania 'Luigi Vanvitelli'

    Naples, Italy

  • West London NHS Trust

    London, United Kingdom

Conditions

Explore the condition pages connected to this study.